Monoamine oxidases (MAOs, E.C. 1.4.3.4) exist in most bodily tissues and in the mitochondrial outer membrane; they catalyze the oxidation of pharmacologically important neurotransmitting monoamines [1] . MAOs belong to the flavin-containing amine oxidoreductase family and are divided into two isoforms, MAO-A and MAO-B. Although their substrate specificity overlaps, MAO-A prefers catecholamines and other biogenic amines, such as norepinephrine and epinephrine, whereas MAO-B has a preference for benzylamine and 2-phenylethylamine [2] . MAO-A is related to depression and anxiety, whereas MAO-B is a target in the treatment of Alzheimer's and Parkinson's diseases [3, 4] . MAO inhibitors are categorized as selective MAO-A, selective MAO-B, or nonselective inhibitors; and they are also grouped as reversible versus irreversible [5] . Potent and reversible inhibitors for MAO-A and -B have been reported based on synthetic compounds or natural products [6] [7] [8] [9] .
Natural products, especially from herbal sources, have been extensively explored for the discovery of novel MAO inhibitors, as described in several reviews [2, [10] [11] [12] . From microbial sources, MAO inhibitory activity was first reported for pimprinine, trans-cinnamic acid amide, and phenethylamine from three strains of Streptomyces with high IC 5 0 values (38-760 μM) [13] . Since that time, only Two piloquinone derivatives isolated from Streptomyces sp. CNQ-027 were tested for the inhibitory activities of two isoforms of monoamine oxidase (MAO), which catalyzes monoamine neurotransmitters. The piloquinone 4,
]pyran-6-one (1) was found to be a highly potent inhibitor of human MAO-B, with an IC 5 0 value of 1.21 µM; in addition, it was found to be highly effective against MAO-A, with an IC Keywords: Monoamine oxidase, piloquinone, Streptomyces sp. CNQ-027, potent selective inhibitor, competitive inhibitor limited information about MAO inhibitors has been reported from microbial metabolites [14] [15] [16] . To explore and extend the screening of MAO inhibitors, we selected bacterial and fungal metabolites as attractive sources for investigation, especially marine microorganisms. Marine actinomycetes have been investigated as drug-discovery sources [17] . Recently, MAO-A selective inhibitory activity was reported by a compound anithiactin from a Streptomyces sp., isolated from tidal flats or deep-sea sediments [15] .
In this study, we examined the inhibition of recombinant human MAO-A and MAO-B by two piloquinone compounds isolated from the bacterium Streptomyces sp. CNQ-027, and we describe the potent inhibitory activity of these compounds against MAO enzymes.
Streptomyces sp. CNQ-027 was isolated from sediment gathering up the coast of southern California [18] . A sequence of 16S rRNA from this strain was 97.6% identical to that of a marine-derived Streptomyces marinus. The bacterial strain Streptomyces sp. CNQ-027 was cultured in thirty-two 2.5 L Ultra Yield Flasks, each containing 1 L (750 ml natural seawater and 250 ml of distilled water) of SYP medium (10 g soluble starch, 4 g yeast extract, 2 g peptone, 10 g CaCO [21] .
Benzylamine, kynuramine, toloxatone, lazabemide, and recombinant human MAO-A and MAO-B were purchased from Sigma-Aldrich (USA). Clorgyline and pargyline were from a monoamine oxidase kit supplied by BioAssay Systems (USA). The initial rates of oxidation were measured in a 1 ml cuvette containing 50 mM of sodium phosphate (pH 7.4) at 25ºC, as described previously, except for the substrate concentrations and assay times [15, 16] . In this study, the activity of MAO-A was assayed with 0.06 mM of kynuramine as the substrate at 316 nm for 20 min, whereas that of MAO-B was assayed with 0.6 mM of benzylamine at 250 nm for 30 min. MAO-B compared with for MAO-A, with a selectivity index value of 5.35 (Table 1) . However, 2 was moderately effective for the inhibition of MAO-B (IC > 80 μM). Compound 1 showed more potent inhibitory activity for MAO, compared with that of 2. This result implies that ester functionality in the ring system is crucial for bioactivity and could be a highly important pharmacophore for MAO inhibitory activity in this class of natural products.
In addition, the time-dependency of the inhibition of MAO-A or -B by 1 and MAO-B by 2 was investigated [16, 22] . The remaining activities of MAO-A and -B were determined with 0.06 mM of kynuramine and 0.6 mM of benzylamine, respectively, after various periods of preincubation (up to 30 min) with 1 or 2 at 25ºC. It was observed that the activity was almost the same as the preincubation time (Fig. 2) , showing that the inhibition of MAO-A and -B using 1 or 2 was not time-dependent.
The recovery of enzyme activity was also analyzed according to the previously described dilution, with a slight modification [16, 23] . Excess 1 (100 × IC ), from the commencement of the experiment. Toloxatone and lazabemide were used as reversible inhibitor references for MAO-A and -B, respectively, whereas clorgyline and pargyline were used as irreversible inhibitor references for MAO-A and -B, respectively. The activities of MAO-A and -B by 1 under the diluted condition were almost recovered (89.0% and 89.6%, respectively) to that under the undiluted condition. However, clorgyline showed to about half the original activity level (47.2%) and pargyline showed no activity (Fig. 3) . These results suggest that 1 is a reversible rather than an irreversible inhibitor.
The kinetics of the inhibition of recombinant human MAO-A and MAO-B by 1 were studied using a spectrophotometric assay with kynuramine and benzylamine as values (38-760 μM) using a rat liver enzyme preparation [13] . 5-Methylmellein and nectriapyrone from fungal strain 8082 inhibited MAO in mouse brains (IC [26] . Compared with these compounds, the piloquinone 1 shows the best inhibitory activity for MAO-B.
Although the IC value of 1 for MAO-B (1.21 μM) is higher than that of lazabemide (0.12 μM) ( Table 1) , which is used as a drug for Parkinson's disease, and is about twice that of maackiain (0.68 μM) [27] , it might be suggested that microbial metabolites or piloquinones might be good The initial velocity was expressed as an increased absorbance per minute. Substrates were used at five different concentrations [1] represents the compound 1.
sources for the discovery of treatment candidates for Parkinson's and Alzheimer's diseases, and antidepressant agents.
The results of the present study suggest that 1 is a potent selective inhibitor of MAO-B and can be considered as a new potential lead compound for the further development of MAO inhibitors.
